Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Organogenesis stock
Learn how to easily invest in Organogenesis stock.
Organogenesis Holdings Inc is a drug manufacturers-specialty & generic business based in the US. Organogenesis shares (ORGO) are listed on the NASDAQ and all prices are listed in US Dollars. Organogenesis employs 910 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Organogenesis
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – ORGO – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Organogenesis stock price (NASDAQ: ORGO)Use our graph to track the performance of ORGO stocks over time.
Organogenesis shares at a glance
|Latest market close||$7.63|
|52-week range||$7.64 - $24.34|
|50-day moving average||$9.78|
|200-day moving average||$14.57|
|Wall St. target price||$24.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.46|
Buy Organogenesis shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Organogenesis stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Organogenesis price performance over time
|1 week (2022-01-14)||-9.38%|
|1 month (2021-12-22)||-23.93%|
|3 months (2021-10-22)||-28.02%|
|6 months (2021-07-22)||-48.79%|
|1 year (2021-01-22)||-27.81%|
|2 years (2020-01-22)||52.30%|
|3 years (2019-01-22)||21.47|
|5 years (2017-01-20)||9.88|
Is Organogenesis stock undervalued or overvalued?
Valuing Organogenesis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Organogenesis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Organogenesis's P/E ratio
Organogenesis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, Organogenesis shares trade at around 18x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Organogenesis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $85 million.
The EBITDA is a measure of a Organogenesis's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$446.3 million|
|Operating margin TTM||16.94%|
|Gross profit TTM||$251 million|
|Return on assets TTM||15.32%|
|Return on equity TTM||48.88%|
|Market capitalisation||$1.1 billion|
TTM: trailing 12 months
Organogenesis share dividends
We're not expecting Organogenesis to pay a dividend over the next 12 months.
Organogenesis share price volatility
Over the last 12 months, Organogenesis's shares have ranged in value from as little as $7.64 up to $24.336. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Organogenesis's is 1.5501. This would suggest that Organogenesis's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Organogenesis Holdings Inc. , a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic allograft wound covering and surgical barrier for application in the care of chronic and acute wounds or surgical implantation in spine, orthopedic, and sports medicine applications; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft, a dermal substitute for the treatment of DFUs; NuShield, a dehydrated placental tissue wound covering and surgical barrier applied to the target tissue to support native healing; and PuraPly Antimicrobial, an antimicrobial barrier skin substitute to treat chronic and acute wounds. Its surgical and sports medicine products comprise NuCel, a surgically implanted allograft used primarily in spinal and orthopedic surgical applications; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor, a chorionic membrane wound covering; TransCyte, a bioengineered tissue for the treatment of partial thickness burns; and Gintuit, a bioengineered bi-layered living cellular tissue for the treatment of mucogingival conditions in adults. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.
Organogenesis in the news
Markets are expected to remain on edge as the Fed meets in the week ahead
ORGO Investors Have Opportunity to Lead Organogenesis Holdings Inc. Securities Fraud Lawsuit
Netflix quietly admits streaming competition is eating into growth
Frequently asked questionsWhat percentage of Organogenesis is owned by insiders or institutions?
Currently 63.209% of Organogenesis shares are held by insiders and 42.418% by institutions. How many people work for Organogenesis?
Latest data suggests 910 work at Organogenesis. When does the fiscal year end for Organogenesis?
Organogenesis's fiscal year ends in December. Where is Organogenesis based?
Organogenesis's address is: 85 Dan Road, Canton, MA, United States, 02021 What is Organogenesis's ISIN number?
Organogenesis's international securities identification number is: US68621F1021 What is Organogenesis's CUSIP number?
Organogenesis's Committee on Uniform Securities Identification Procedures number is: 68621F102
More guides on Finder
Dogecoin jumps 10% on word you can use it to buy Tesla merch
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
Thursday’s top U.S. stocks: Taiwan Semiconductor Manufacturing Company Ltd. (TSM ↑8.4%), Lam Research Corporation (LRCX ↑6.1%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
How to buy Nexalin Technology (NXL) stock when it goes public
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
Ask an Expert